PMID- 35023407
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20220317
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 31
IP  - 3
DP  - 2022 Mar
TI  - The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus 
      patients: A systematic review.
PG  - 287-296
LID - 10.1177/09612033211067985 [doi]
AB  - OBJECTIVE: Many rheumatologists are inundated with questions about what "natural 
      remedies" and "anti-autoimmune diets" exist for decreasing Systemic Lupus 
      Erythematosus (SLE) disease activity. Over the last three decades, there has been 
      an abundance of data from several different trials about omega-3 fatty acids 
      sourced from fish oil, but the findings have been contradictory. This review 
      seeks to present this data so that evidence-based recommendations can be given to 
      patients, supporting the use of an adjuvant regimen with their present 
      immunosuppression. METHODS: A literature search was conducted using the PubMed, 
      Google Scholar, MEDLINE, and Scopus electronic databases to retrieve relevant 
      articles for this review. Trials conducted on human subjects with SLE with full 
      publications in English were included from 1 January 1980 to 1 April 2021. The 
      impact of fish oil-derived omega-3 fatty acid supplementation on specific 
      clinical features, the innate and adaptive immune response, biomarkers, and 
      disease activity measures were assessed. The initial search yielded 7519 
      articles, but only 13 met our criteria and were eligible for this review. 
      RESULTS: Data from thirteen articles were assessed. Ten trials assessed disease 
      activity as an outcome, with eight trials demonstrating an improvement in 
      patients in the omega-3 fatty acid group as assessed by a validated clinical tool 
      or individual patient criteria. There was a significant improvement in Systemic 
      Lupus Activity Measure-Revised (SLAM-R) scores at week 12 (p = .009) and week 24 
      (p < .001). Additionally, a reduction of urinary 8-isoprostane, a non-invasive 
      marker of disease activity, was observed. There was no treatment benefit seen 
      with respect to renal parameters such as serum creatinine or 24-hour urine 
      protein; or systemic parameters such as C3, C4, or anti-double stranded DNA 
      (anti-dsDNA) levels regardless of the dose of the omega-3 LUPUS fatty acids or 
      duration of the trial. CONCLUSION: While there is conflicting evidence about the 
      benefits of omega-3 fatty acid supplementation on SLE disease activity, specific 
      measures have demonstrated benefits. Current data show that there is a potential 
      benefit on disease activity as demonstrated by SLAM-R, Systemic Lupus 
      Erythematosus Disease Activity Index (SLEDAI), and British Isles Lupus Assessment 
      Group (BILAG) scores and plasma membrane arachidonic acid composition and urinary 
      8-isoprostane levels, with minimal adverse events.
FAU - Ramessar, Nina
AU  - Ramessar N
AUID- ORCID: 0000-0001-6785-6725
AD  - Rheumatology, Rutgers Robert Wood Johnson Medical School (RWJMS), New Brunswick, 
      NJ, USA.
FAU - Borad, Abhilasha
AU  - Borad A
AD  - Medicine, 43982Rutgers Robert Wood Johnson Medical School (RWJMS), New Brunswick, 
      NJ, USA.
FAU - Schlesinger, Naomi
AU  - Schlesinger N
AD  - Rheumatology, Rutgers Robert Wood Johnson Medical School (RWJMS), New Brunswick, 
      NJ, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20220113
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
SB  - IM
MH  - Biomarkers/blood
MH  - Dietary Supplements
MH  - *Fatty Acids, Omega-3/pharmacology/therapeutic use
MH  - Fish Oils/therapeutic use
MH  - Humans
MH  - *Lupus Erythematosus, Systemic/immunology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Systemic lupus erythematosus
OT  - fish oil
OT  - omega-3 fatty acids
EDAT- 2022/01/14 06:00
MHDA- 2022/03/18 06:00
CRDT- 2022/01/13 08:42
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2022/01/13 08:42 [entrez]
AID - 10.1177/09612033211067985 [doi]
PST - ppublish
SO  - Lupus. 2022 Mar;31(3):287-296. doi: 10.1177/09612033211067985. Epub 2022 Jan 13.